Birmingham Hip Resurfacing Safe, Effective Over 15 Years
By Lori Solomon HealthDay Reporter
MONDAY, April 21, 2025 -- Birmingham hip resurfacing (BHR) is effective and shows implant longevity in appropriately selected patients, according to a study published in the March 19 issue of the Journal of Bone & Joint Surgery.
William A. Zuke, M.D., from Washington University in St. Louis, and colleagues evaluated BHR survivorship, as well as radiographic and clinical outcomes, at long-term follow-up. The analysis included 224 patients meeting the current indications for BHR (i.e., men younger than 60 years of age with a preoperative diagnosis of osteoarthritis and proximal femoral bone able to accept a component size ≥48 mm) who were followed for a mean of 14 years. Patient-reported outcomes (PROs) were compared to those for matched patients who had undergone total hip arthroplasty (THA).
The researchers found that survivorship free from any revision and from aseptic revision was 96.0 and 97.4 percent, respectively, at 15 years. The median serum cobalt level was 1.4 parts per billion, while the median serum chromium level was 1.5 parts per billion. PROs were similar to those reported by patients who had undergone THA. Similarly, equal proportions of patients remained active, although the BHR group trended toward more remaining highly active.
"On the basis of implant survival and level of satisfaction, this long-term follow-up study supports the use of BHR in select patients," the authors write. "Long-term monitoring is suggested for patients with pain or elevated metal ions."
Smith & Nephew provided funding for the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-04-22 06:00
Read more

- Six Months of Breastfeeding Tied to Lower Odds of Developmental Delays
- 93,022 Firearm Injury Emergency Visits Seen From January 2018 to August 2023
- Guideline Adherence Suboptimal for Chlamydia, Gonorrhea Treatment
- Five Top CDC Leaders Step Down Amid Wave of Departures
- Vaccine Panel Urges More Protection Against RSV, Meningitis and Chikungunya
- Biological Link Identified Between Heavy Weed Use And Psychosis
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions